Chardan lowered the firm’s price target on uniQure to $27 from $45 and keeps a Buy rating on the shares after the company announced interim data from their Phase 1/2 HD-GeneTRX1 clinical trial of their AAV5-based gene therapy, AMT-130, at a low dose (6e12 vg) and high dose (6e13 vg) for the treatment of Huntington’s disease. The data “lacked conviction”, and the firm has adjusted its model to account for a longer development path forward for AMT-130 where longer, larger studies are likely required to verify clinical benefit, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on QURE:
- uniQure selloff on AMT-130 update ‘appears overdone,’ says H.C. Wainwright
- uniQure Tanks on Interim Data in Huntington’s Disease
- uniQure announces update on Phase I/II trial of AMT-130
- uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure achieves $100M milestone related to hemophilia B gene therapy